Cofa apha ukuba le ngxelo yakho!

Uphononongo olutsha lwesitofu sokugonya umhlaza e-China Yaziswa

Ibhalwe ngu umhleli

I-Innovent Biologics, Inc. (Innovent), inkampani yehlabathi ye-biopharmaceutical eyenza, ivelise kwaye ithengise amayeza akumgangatho ophezulu wokunyanga umhlaza, i-metabolic, i-autoimmune kunye nezinye izifo eziphambili, kunye ne-NeoCura Bio-Medical Technology Co., Ltd. I-NeoCura), inkampani ehamba phambili ye-AI-inikwe amandla e-RNA ye-biotech ye-biotech yenkampani ezinikele ekwakheni iqonga leziyobisi le-RNA ephezulu yehlabathi, namhlanje ibhengeze ngokudibeneyo ukuba bangene kwisivumelwano sentsebenziswano sobuchule ukwenza uphando lwezonyango e-China kunyango oludityanisiweyo lwe-sintilimab. ukusuka kwi-Innovent kunye nesitofu sokugonya se-neoantigen esizimeleyo i-NEO_PLIN2101 evela kwi-NeoCura.

Print Friendly, PDF & Email

I-Innovent iya kusebenzisana ne-NeoCura e-China ukuvavanya ukhuseleko, i-pharmacokinetics, i-pharmacodynamics kunye nokusebenza kwangaphambili konyango oludibeneyo usebenzisa i-sintilimab evela kwi-Innovent kunye ne-NEO_PLIN2101 evela kwi-NeoCura kwizigulana ezinomhlaza, ukuqhubela phambili uphuhliso lwekliniki lwe-immunotherapy edibeneyo yamathumba amaninzi aqinileyo kunye nokulungiselela ukungenisa. isicelo sechiza esitsha soPhando (IND) kuLawulo lweeMveliso zoNyango lweSizwe (NMPA) kungekudala.

UGqr. Liu Yongjun, uMongameli we-Innovent, uthe: “Sichukumisekile ngumbhobho we-R&D owahluliweyo we-NeoCura kunye neqela lophando lamazwe ngamazwe, kwaye siyakuvuyela ukungena kule ntsebenziswano icwangcisiweyo ukuhlola ixabiso lekliniki le-sintilimab ngokudityaniswa nogonyo lwe-neoantigen lwamathumba aqinileyo. . I-Innovent inombhobho owomeleleyo onobuchule obuqinileyo kwi-immunology kunye nebhayoloji yomhlaza. Sithetha nje, sinamayeza amatsha amahlanu avunyiweyo aza asungulwa e-China kwaye azakuba namachiza angaphezu kwe-10 aza kuqaliswa kule minyaka mi-2-3 izayo. Iqonga lethu elidityaniswe ngokupheleleyo liqokelele iR&D eyomeleleyo, uphuhliso lwezonyango kunye nesakhono sorhwebo kwaye lilungele amaqabane asekhaya nakwamanye amazwe. Sikwanethemba lokuphonononga ngakumbi amathuba amatsha ekwandiseni izalathisi kunye nokuphucula ukusebenza konyango lwe-sintilimab ngokudityaniswa nonyango lwenoveli. Sijonge phambili kwintsebenziswano ebanzi nenzulu phakathi kwala maqela mabini kwixesha elizayo. “

UGqr. Wang Yi, umseki weNeoCura, wathi: “Okwangoku, izitofu zokugonya i<em>neoantigen ziyindlela entsha yonyango esakhulayo ehlabathini lonke. I-NeoCura ibigxile kwi-R&D yezitofu zokugonya i-tumor neoantigen ukusukela oko yasekwa, ngethemba lokoyisa imiceli mngeni yonyango olukhoyo kunyango lwamathumba aqinileyo ngokusetyenziswa kwetekhnoloji entsha. Intsebenziswano kunye ne-Innovent iya kudlala indima ye-synergistic yogonyo lwe-neoantigen lomntu kunye ne-monoclonal antibody kunye nokuphonononga ngokudibeneyo isiphumo sonyango oludityanisiweyo kunyango lwamathumba aqinileyo, ekulindeleke ukuba iphucule inqanaba lokuphendula lenjongo yonyango lomhlaza kunye nokuzisa amathuba amatsha. kwiirejimeni ezidityanisiweyo zomhlaza.”

Print Friendly, PDF & Email

Malunga nombhali

umhleli

Umhleli oyintloko nguLinda Hohnholz.

Shiya Comment